摘要凡德他尼 VandetanibVandetanib is an orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity...

摘要 索拉非尼 SorafenibSorafenib is a synthetic compound targeting growth signaling and angiogenesis.

摘要帕唑帕尼 PazopanibPazopanib is an approved drug, is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineo...

摘要樂伐替尼 LenvatinibLenvatinib,also known as E7080,is a synthetic,orally available inhibitor of vascular endothelial growth factor receptor...

摘要卡博替尼 CabozantinibCabozantinib, also known as XL-184 or BMS-907351, is an orally bioavailable, small molecule receptor tyrosine kinase ...

摘要 KPT-330 SelinexorSelinexor, also known as KPT-330, is an orally bioavailable, potent and selective XPO1/CRM1 Inhibitor.

摘要格拉吉布 GlasdegibGlasdegib, also known as PF-04449913, is an orally bioavailable small-molecule inhibitor of the Hedgehog (Hh) signaling ...

摘要CAL-101 IdelalisibIdelalisib, also known as CAL-101, is a PI3K-delta inhibitor with potential immunomodulating and antineoplastic acti...

摘要IPI 145 DuvelisibAlso known as IPI-145 and INK-1197, is an orally bioavailable, highly selective and potent small molecule inhibitor o...

摘要 BAY 80-6946 CopanlisibCopanlisib also known as BAY 80-6946, is a potent phosphoinositide 3-kinase (PI3K) inhibitor.

摘要阿培利司 AlpelisibAlpelisib, also known as BLY719, is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential...

摘要BMN 673 TalazoparibTalazoparib, also known as BMN-673 and MDV-3800,is an orally bioavailable inhibitor of the nuclear enzyme poly(ADP-...

摘要魯卡帕尼 RucaparibRucaparib is a tricyclic indole poly(ADP-Ribose) polymerase (PARP1) inhibitor with potential chemosensitizing, radiosens...

摘要尼拉帕尼 NiraparibNiraparib, also known as MK4827, is an orally active, potent and selective poly(ADP-Ribose) polymerase (PARP) inhibitor ...

摘要奧拉帕尼 OlaparibOlaparib, also known as AZD-2281 or KU-59436 , is a small molecule inhibitor of the nuclear enzyme poly(ADP-ribose) polym...

摘要拉羅替尼 LarotrectinibLarotrectinib, also known as ARRY-470 and LOXO-101, is an orally bioavailable, potent, ATP-competitive inhibitor of ...

摘要恩曲替尼 EntrectinibEntrectinib, also known as RXDX-101 and NMS-E628, is an oral small molecule inhibitor of TrkA, TrkB and TrkC, as well ...

摘要依維莫司 EverolimusEverolimus, also known as RAD001, is a derivative of the natural macrocyclic lactone sirolimus with immunosuppressant a...

摘要曲美替尼 TrametinibTrametinib, also known as GSK1120212, is a n orally bioavailable inhibitor of mitogen-activated protein kinase kinase (...

摘要考比替尼 CobimetinibCobimetinib, also known as GDC-0973 and XL-518, RG 7420, is an orally bioavailable small-molecule inhibitor of mitogen...

摘要 貝美替尼 BinimetinibBinimetinib, also known as MEK162 (ARRY-162), is an oral, highly selective MEK inhibitor.

摘要艾伏尼布 Ivosidenib Ivosidenib, also known as AG-120 and RG-120, is an orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1...

摘要伊那尼布 EnasidenibEnasidenib, also known as AG-221 and CC-90007, is a potent and selective IDH2 inhibitor with potential anticancer activ...

摘要瑞戈非尼 RegorafenibRegorafenib, also known as BAY 73-4506 ; is an orally bioavailable small molecule with potential antiangiogenic and an...

摘要魯索替尼 RuxolitinibAlso known as INC424 and INCB18424 or INCB018424, is an orally bioavailable Janus-associated kinase (JAK) inhibitor wi...

摘要厄達替尼 ErdafitinibErdafitinib, also known as JNJ-42756493, is a potent and selective orally bioavailable, pan fibroblast growth factor r...

摘要米哚妥林 MidostaurinMidostaurin, also known as PKC-412, PKC-412A and CGP 41251; is a synthetic indolocarbazole multikinase inhibitor with ...

摘要吉列替尼 GilteritinibGilteritinib, also known as ASP2215, is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity agains...

摘要來那替尼 NeratinibNeratinib, also known as HKI-272 or PB272, is an orally available, irreversible inhibitor of the HER-2 receptor tyrosine...

摘要 奧瑞替尼 OsimertinibOsimertinib, also known as AZD-9291 and Mereletinib, is a third-generation EGFR inhibitor,

摘要達克替尼 DacomitinibDacomitinib, also known as PF-299 and PF-00299804 ; or PF299804, is an orally bioavailable, highly selective, second-g...

摘要吡昔替尼 PexidartinibPexidartinib, also know as PLX-3397, is a CSF1R inhibitor with IC50 of 20 nM in development by Plexxikon for the trea...

摘要瑞博西尼 RibociclibRibociclib Free Base, also known as LEE011, is an orally available cyclin-dependent kinase (CDK) inhibitor targeting cy...

摘要帕布昔利布 PalbociclibPalbociclib, also known as PD-0332991, is an orally available cyclin-dependent kinase (CDK) inhibitor with potential ...

摘要?，斘髂?AbemaciclibAlso known as LY2835219, is orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1)...

摘要贊魯替尼 ZanubrutinibZanubrutinib, aslo known as BGB-3111, is a potent and highly selective small molecule BTK inhibitor for the potential...

摘要依魯替尼 IbrutinibIbrutinib, also known as PCI-32765, is a potent and orally active BTK inhibitor. Ibrutinib binds to and inhibits BTK act...

摘要阿卡替尼 AcalabrutinibAcalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potent...

摘要康奈非尼 EncorafenibEncorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity...

摘要達帕菲尼 DabrafenibDabrafenib, also known as GSK2118436 , is an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antin...

摘要維羅非尼 VemurafenibAlso known as PLX4032, RG7204 or RO5185426, is an orally bioavailable, ATP-competitive, small-molecule inhibitor of BR...

摘要普納替尼 PonatinibPonatinib is an orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic...

摘要尼羅替尼 NilotinibNilotinib, also known as AMN107, is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-re...

摘要 DasatinibDasatinib is a potent inhibitor of the non-receptor tyrosine kinases Abl and Src as well as other members of the Src family.

摘要伯舒替尼 BosutinibBosutinib, also known as SKI-606, is a synthetic quinolone derivative and dual kinase inhibitor that targets both Abl an...